Isabelle Mahé on Reduced Dose Apixaban and Cancer-Associated VTE
Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, shared on LinkedIn:
”Just published in the Lancet Haematology
In this post-hoc analysis of the API-CAT Study, including patients with CAT receiving extended anticoagulant with apixaban.
- 4 clinical predictors were significantly associated with increased CRB risk : anaemia and/or thrombocytopenia, age ≥75, PE as the index event, and male sex.
- 3 of them are also significant predictors of MB
- Identified predictors are non modifiable
- No cancer-related predictors associated with increased CRB risk
- Associations are consistent across cancer sites
- No evidence of interaction with apixaban dose
To reach the publication.
To reach the Comment.
As a reminder, in CAT extended treatment NEJM
Reduced dose apixaban is non inferior to full-dose on VTE recurrence, and associated with a 25% reduction in the risk of CRB
To reach the publication: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. DOI 10.1056/NEJMoa2416112”
Read the full article here.
Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 9, 2026, 06:39Chaza Alaji: How Hemophilia Became a Disease of Precision Medicine
-
Sep 9, 2026, 05:52Faheema Hasan: New ASH 2026 Guidelines Redefine Initial and Second-Line ITP Therapy
-
Sep 9, 2026, 05:43Thomas Pincez: Clonal Hematopoiesis Linked to Increased Risk of Autoimmune Hemolytic Anemia
-
Sep 9, 2026, 05:33Marianne Yee: Sickle Cell Disease and the Human Side of Medical Research
-
Sep 8, 2026, 16:14Heghine Khachatryan: Colombo 2026 Insights on Point-of-Care Ultrasound in Hemophilia Joint Care
-
Sep 8, 2026, 15:57Flora Peyvandi: Efficiency Meets Innovation in Hemophilia B Gene Therapy
-
Sep 8, 2026, 15:48Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?
-
Sep 8, 2026, 15:34Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
-
Sep 8, 2026, 15:31Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First